S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
High-speed rail was touted as a game-changer in Britain. Costs are making the government think twice
His system isolated NVIDIA - Here's His Next Buy. (Ad)
Writers Guild and Hollywood studios reach tentative deal to end strike. No deal yet for actors
The threat of wildfires is rising. So are new artificial intelligence solutions to fight them
His system isolated NVIDIA - Here's His Next Buy. (Ad)
Facial recognition technology jailed a man for days. His lawsuit joins others from Black plaintiffs
The UN's top tech official discusses AI, bringing the world together and what keeps him up at night
Pentagon Consultant—Here's how Biden Wins Landslide Re-election (Ad)
Stock market today: Asian shares mostly lower after Wall St has its worst week in 6 months
Canadian autoworkers ratify new labor agreement with Ford
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
High-speed rail was touted as a game-changer in Britain. Costs are making the government think twice
His system isolated NVIDIA - Here's His Next Buy. (Ad)
Writers Guild and Hollywood studios reach tentative deal to end strike. No deal yet for actors
The threat of wildfires is rising. So are new artificial intelligence solutions to fight them
His system isolated NVIDIA - Here's His Next Buy. (Ad)
Facial recognition technology jailed a man for days. His lawsuit joins others from Black plaintiffs
The UN's top tech official discusses AI, bringing the world together and what keeps him up at night
Pentagon Consultant—Here's how Biden Wins Landslide Re-election (Ad)
Stock market today: Asian shares mostly lower after Wall St has its worst week in 6 months
Canadian autoworkers ratify new labor agreement with Ford
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
High-speed rail was touted as a game-changer in Britain. Costs are making the government think twice
His system isolated NVIDIA - Here's His Next Buy. (Ad)
Writers Guild and Hollywood studios reach tentative deal to end strike. No deal yet for actors
The threat of wildfires is rising. So are new artificial intelligence solutions to fight them
His system isolated NVIDIA - Here's His Next Buy. (Ad)
Facial recognition technology jailed a man for days. His lawsuit joins others from Black plaintiffs
The UN's top tech official discusses AI, bringing the world together and what keeps him up at night
Pentagon Consultant—Here's how Biden Wins Landslide Re-election (Ad)
Stock market today: Asian shares mostly lower after Wall St has its worst week in 6 months
Canadian autoworkers ratify new labor agreement with Ford
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
High-speed rail was touted as a game-changer in Britain. Costs are making the government think twice
His system isolated NVIDIA - Here's His Next Buy. (Ad)
Writers Guild and Hollywood studios reach tentative deal to end strike. No deal yet for actors
The threat of wildfires is rising. So are new artificial intelligence solutions to fight them
His system isolated NVIDIA - Here's His Next Buy. (Ad)
Facial recognition technology jailed a man for days. His lawsuit joins others from Black plaintiffs
The UN's top tech official discusses AI, bringing the world together and what keeps him up at night
Pentagon Consultant—Here's how Biden Wins Landslide Re-election (Ad)
Stock market today: Asian shares mostly lower after Wall St has its worst week in 6 months
Canadian autoworkers ratify new labor agreement with Ford
NASDAQ:CRBP

Corbus Pharmaceuticals (CRBP) Stock Forecast, Price & News

$6.80
+0.30 (+4.62%)
(As of 09/22/2023 ET)
Compare
Today's Range
$6.50
$7.00
50-Day Range
$6.15
$7.77
52-Week Range
$2.11
$13.17
Volume
8,674 shs
Average Volume
10,394 shs
Market Capitalization
$30.06 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$12.50

Corbus Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
83.8% Upside
$12.50 Price Target
Short Interest
Healthy
1.71% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.65
Upright™ Environmental Score
News Sentiment
-0.25mentions of Corbus Pharmaceuticals in the last 14 days
Based on 3 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($11.52) to ($10.29) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.26 out of 5 stars

Medical Sector

323rd out of 962 stocks

Pharmaceutical Preparations Industry

140th out of 453 stocks


CRBP stock logo

About Corbus Pharmaceuticals (NASDAQ:CRBP) Stock

Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells for the treatment of solid tumors; CRB-913, an endocannabinoid small molecule drug for the treatment of obesity and related metabolic diseases; and lenabasum, an oral molecule that selectively activates cannabinoid receptor type 2 (CB2), which is in Phase II clinical trial or the treatment of inflammation and fibrosis. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, including the Jenrin library of approximately 600 compounds, and multiple issued and pending patent filings. The company was incorporated in 2009 and is based in Norwood, Massachusetts.

CRBP Price History

CRBP Stock News Headlines

His system isolated NVIDIA - Here's His Next Buy.
Most investors don't know the truth about A.I. 50-year Wall Street Insider Marc Chaikin reveals what you should be doing to profit. Learn more here.
CRBP - Corbus Pharmaceuticals Holdings, Inc.
His system isolated NVIDIA - Here's His Next Buy.
Most investors don't know the truth about A.I. 50-year Wall Street Insider Marc Chaikin reveals what you should be doing to profit. Learn more here.
Corbus Pharmaceuticals (NASDAQ: CRBP)
See More Headlines
Receive CRBP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Corbus Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

CRBP Company Calendar

Last Earnings
8/08/2023
Today
9/24/2023
Next Earnings (Estimated)
11/14/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:CRBP
Employees
33
Year Founded
2009

Price Target and Rating

Average Stock Price Forecast
$12.50
High Stock Price Forecast
$22.00
Low Stock Price Forecast
$3.00
Forecasted Upside/Downside
+83.8%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Net Income
$-42,350,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$880,000.00
Book Value
$7.91 per share

Miscellaneous

Free Float
4,123,000
Market Cap
$30.06 million
Optionable
Optionable
Beta
2.29

Social Links

13 Stocks Institutional Investors Won't Stop Buying Cover

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

Key Executives

  • Dr. Yuval Cohen Ph.D. (Age 48)
    CEO & Director
    Comp: $890.67k
  • Mr. Sean F. Moran CPA (Age 65)
    M.B.A., CPA, MBA, Chief Financial Officer
    Comp: $579.05k
  • Dr. Rachael Brake Ph.D. (Age 51)
    Chief Scientific Officer
    Comp: $552.22k
  • Ted Jenkins
    Sr. Director of Investor Relations & Corp. Communications
  • Ms. Lindsey Smith
    Head of Corp. Communications & Patient Advocacy
  • Ms. Christina Bertsch
    Head of HR













CRBP Stock - Frequently Asked Questions

Should I buy or sell Corbus Pharmaceuticals stock right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Corbus Pharmaceuticals in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" CRBP shares.
View CRBP analyst ratings
or view top-rated stocks.

What is Corbus Pharmaceuticals' stock price forecast for 2023?

2 brokers have issued 1-year target prices for Corbus Pharmaceuticals' shares. Their CRBP share price forecasts range from $3.00 to $22.00. On average, they anticipate the company's stock price to reach $12.50 in the next year. This suggests a possible upside of 83.8% from the stock's current price.
View analysts price targets for CRBP
or view top-rated stocks among Wall Street analysts.

How have CRBP shares performed in 2023?

Corbus Pharmaceuticals' stock was trading at $0.1105 on January 1st, 2023. Since then, CRBP stock has increased by 6,053.8% and is now trading at $6.80.
View the best growth stocks for 2023 here
.

Are investors shorting Corbus Pharmaceuticals?

Corbus Pharmaceuticals saw a decrease in short interest in August. As of August 31st, there was short interest totaling 75,400 shares, a decrease of 6.1% from the August 15th total of 80,300 shares. Based on an average trading volume of 14,600 shares, the days-to-cover ratio is currently 5.2 days. Approximately 1.7% of the company's stock are short sold.
View Corbus Pharmaceuticals' Short Interest
.

When is Corbus Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 14th 2023.
View our CRBP earnings forecast
.

How were Corbus Pharmaceuticals' earnings last quarter?

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) issued its quarterly earnings data on Tuesday, August, 8th. The biopharmaceutical company reported ($2.05) EPS for the quarter, topping the consensus estimate of ($3.10) by $1.05.

What other stocks do shareholders of Corbus Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Corbus Pharmaceuticals investors own include Visa (V), HP (HPQ), Fortive (FTV), Lowe's Companies (LOW), Sorrento Therapeutics (SRNE), Exelixis (EXEL), Matinas BioPharma (MTNB), Inovio Pharmaceuticals (INO) and KushCo (KSHB).

What is Corbus Pharmaceuticals' stock symbol?

Corbus Pharmaceuticals trades on the NASDAQ under the ticker symbol "CRBP."

Who are Corbus Pharmaceuticals' major shareholders?

Corbus Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional shareholders include BlackRock Inc. (1.85%) and Dimensional Fund Advisors LP (0.72%). Insiders that own company stock include Craig Stuart Millian, Sean F Moran and Yuval Cohen.
View institutional ownership trends
.

How do I buy shares of Corbus Pharmaceuticals?

Shares of CRBP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Corbus Pharmaceuticals' stock price today?

One share of CRBP stock can currently be purchased for approximately $6.80.

How much money does Corbus Pharmaceuticals make?

Corbus Pharmaceuticals (NASDAQ:CRBP) has a market capitalization of $30.06 million and generates $880,000.00 in revenue each year. The biopharmaceutical company earns $-42,350,000.00 in net income (profit) each year or ($11.0021) on an earnings per share basis.

How can I contact Corbus Pharmaceuticals?

Corbus Pharmaceuticals' mailing address is 500 River Ridge Drive, Norwood MA, 02062. The official website for the company is www.corbuspharma.com. The biopharmaceutical company can be reached via phone at (617) 963-0100, via email at ir@corbuspharma.com, or via fax at 617-663-6085.

This page (NASDAQ:CRBP) was last updated on 9/24/2023 by MarketBeat.com Staff

My Account -